Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 4670 | 9.77 |
09:34 ET | 676 | 9.74 |
09:39 ET | 7713 | 9.7829 |
09:45 ET | 100 | 9.8 |
09:52 ET | 227 | 9.74 |
09:54 ET | 1755 | 9.7 |
09:56 ET | 200 | 9.625 |
09:57 ET | 200 | 9.66 |
10:03 ET | 200 | 9.64 |
10:10 ET | 500 | 9.7 |
10:14 ET | 1397 | 9.67 |
10:15 ET | 300 | 9.7 |
10:17 ET | 100 | 9.7 |
10:19 ET | 700 | 9.69 |
10:21 ET | 860 | 9.67 |
10:26 ET | 290 | 9.56 |
10:28 ET | 231 | 9.6 |
10:32 ET | 100 | 9.59 |
10:33 ET | 100 | 9.55 |
10:35 ET | 200 | 9.58 |
10:37 ET | 173 | 9.582 |
10:42 ET | 200 | 9.57 |
10:44 ET | 100 | 9.58 |
10:46 ET | 200 | 9.545 |
10:48 ET | 200 | 9.56 |
10:51 ET | 100 | 9.585 |
10:55 ET | 300 | 9.615 |
10:57 ET | 500 | 9.62 |
11:00 ET | 100 | 9.615 |
11:02 ET | 400 | 9.66 |
11:04 ET | 484 | 9.64 |
11:08 ET | 200 | 9.64 |
11:09 ET | 400 | 9.63 |
11:13 ET | 1798 | 9.605 |
11:15 ET | 271 | 9.55 |
11:18 ET | 200 | 9.501 |
11:20 ET | 750 | 9.53 |
11:22 ET | 400 | 9.48 |
11:24 ET | 1360 | 9.43 |
11:29 ET | 100 | 9.44 |
11:31 ET | 100 | 9.48 |
11:36 ET | 800 | 9.46 |
11:38 ET | 100 | 9.49 |
11:40 ET | 100 | 9.47 |
11:42 ET | 1412 | 9.48 |
11:44 ET | 200 | 9.51 |
11:45 ET | 100 | 9.515 |
11:47 ET | 379 | 9.48 |
11:49 ET | 300 | 9.49 |
11:51 ET | 100 | 9.485 |
11:54 ET | 100 | 9.49 |
11:56 ET | 400 | 9.505 |
11:58 ET | 100 | 9.52 |
12:00 ET | 100 | 9.54 |
12:02 ET | 200 | 9.535 |
12:03 ET | 1100 | 9.47 |
12:05 ET | 200 | 9.51 |
12:07 ET | 100 | 9.51 |
12:09 ET | 100 | 9.53 |
12:12 ET | 300 | 9.505 |
12:14 ET | 300 | 9.52 |
12:16 ET | 200 | 9.54 |
12:20 ET | 100 | 9.54 |
12:21 ET | 422 | 9.52 |
12:23 ET | 500 | 9.54 |
12:25 ET | 1100 | 9.53 |
12:27 ET | 400 | 9.52 |
12:30 ET | 100 | 9.54 |
12:34 ET | 200 | 9.53 |
12:38 ET | 1200 | 9.54 |
12:41 ET | 804 | 9.545 |
12:43 ET | 754 | 9.54 |
12:45 ET | 266 | 9.5449 |
12:48 ET | 800 | 9.57 |
12:52 ET | 200 | 9.575 |
12:54 ET | 606 | 9.57 |
12:56 ET | 200 | 9.57 |
12:57 ET | 100 | 9.58 |
01:01 ET | 100 | 9.58 |
01:03 ET | 543 | 9.55 |
01:06 ET | 1700 | 9.61 |
01:08 ET | 900 | 9.59 |
01:10 ET | 400 | 9.59 |
01:12 ET | 400 | 9.6 |
01:14 ET | 200 | 9.595 |
01:15 ET | 100 | 9.61 |
01:17 ET | 100 | 9.61 |
01:19 ET | 5335 | 9.63 |
01:21 ET | 3891 | 9.7 |
01:24 ET | 100 | 9.66 |
01:26 ET | 100 | 9.67 |
01:28 ET | 100 | 9.655 |
01:30 ET | 100 | 9.67 |
01:32 ET | 200 | 9.64 |
01:33 ET | 100 | 9.65 |
01:35 ET | 300 | 9.68 |
01:39 ET | 200 | 9.67 |
01:42 ET | 800 | 9.66 |
01:44 ET | 795 | 9.68 |
01:46 ET | 100 | 9.68 |
01:50 ET | 100 | 9.67 |
01:51 ET | 400 | 9.62 |
01:53 ET | 600 | 9.59 |
02:00 ET | 100 | 9.59 |
02:20 ET | 100 | 9.55 |
02:22 ET | 1200 | 9.545 |
02:33 ET | 1052 | 9.563651 |
02:38 ET | 100 | 9.58 |
02:40 ET | 100 | 9.58 |
02:42 ET | 1645 | 9.588 |
02:49 ET | 200 | 9.57 |
02:51 ET | 202 | 9.625 |
02:56 ET | 100 | 9.635 |
02:58 ET | 200 | 9.66 |
03:02 ET | 600 | 9.65 |
03:03 ET | 200 | 9.645 |
03:09 ET | 3111 | 9.65 |
03:12 ET | 100 | 9.65 |
03:16 ET | 407 | 9.64 |
03:20 ET | 300 | 9.65 |
03:21 ET | 100 | 9.66 |
03:23 ET | 800 | 9.67 |
03:27 ET | 528 | 9.63 |
03:30 ET | 700 | 9.65 |
03:32 ET | 524 | 9.6342 |
03:34 ET | 250 | 9.638 |
03:36 ET | 444 | 9.655 |
03:38 ET | 100 | 9.65 |
03:39 ET | 400 | 9.67 |
03:41 ET | 651 | 9.68 |
03:43 ET | 2307 | 9.67 |
03:45 ET | 400 | 9.675 |
03:48 ET | 700 | 9.67 |
03:52 ET | 600 | 9.66 |
03:54 ET | 8674 | 9.65 |
03:56 ET | 9279 | 9.65 |
03:57 ET | 1817 | 9.63 |
03:59 ET | 45693 | 9.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 673.0M | -5.5x | --- |
Tourmaline Bio Inc | 673.1M | -10.5x | --- |
Rapport Therapeutics Inc | 670.8M | -11.8x | --- |
Olema Pharmaceuticals Inc | 662.0M | -5.6x | --- |
Annexon Inc | 656.1M | -5.2x | --- |
Terns Pharmaceuticals Inc | 692.1M | -6.3x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $673.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.